
Figure 1


a
Tissue Samples
Cell Lines
TNBC (n = 7)
Non-TNBC (n = 22)
TNBC (n = 8)
Non-TNBC (n = 6)
Druggable Targets
PSAT1
CPA4
B3GNT5
UBASH3B
CHST3
GSTP1
AK2
PRMT2
MOXD1
AGPAT4
ACOT9
CDK6
HSD11B1L
ALDH1A3
UGP2
HYAL3
PLOD1
MAPK12
ST3GAL6
ESR1
AR
PGR
GATA3
FOXA1



b
siNC
siPSAT1
siB3GNT5
siUBASH3B
siAGPAT4
siACOT9
siCDK6
siHYAL3
siRNA#1
siRNA#2
siNC
siRNA#1
siRNA#2
0.0 0.5 1.0
Relative mRNA expression

Figure 1 – cont'd





Figure 1 – cont'd

h



i






Figure 1 – cont'd

j



k



l




Figure 2



a
TSS
-800bp
ETS binding motifs
Promoter
b
ETS1
Relative mRNA expression
600
400
200
0
SKBR3
MCF7
BT474
T47D
MB361
MB415
MB468
HCC1806
HCC1937
MB231
BT549
Hs578T
MB436
MB157
ETS1
ACTIN
Non-TNBC
TNBC
c
500bp
TSS
1 2 3 4 5 6 7 8
BT549
MB231
IgG
ETS1
% Input
0.15
0.10
0.05
0.00
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
1 2 3 4 5 6 7 8
d
UBASH3B
Relative mRNA expression
1.5
1.0
0.5
0.0
siNC
siETS1#1
siETS1#2
UBASH3B
ETS1
ACTIN

Figure 2 – cont'd




Figure 2 – cont'd




Figure 3



a
UBASH3B
miR200a MRE
TAA
3'UTR
b
miR200a
Relative miR expression
SKBR3
MCF7
BT474
T47D
MB361
MB415
MB468
HCC1806
HCC1937
MB231
BT549
Hs578T
MB436
MB157
Non-TNBC
TNBC
c
GCAGAGC
Mutant seq
3' UGUAGCAAUGGUCUGUCACAAU miR200a
+553
5' CUAGCCCCCAUACACCAGUGUUG UBASH3B-MRE1
3' UGUAGCAAUGGUCUGUCACAAU miR200a
+2822
5' AAUCCGGUAAUGCCCCAGUGUUA UBASH3B-MRE2
3' UGUAGCAAUGGUCUGUCACAAU miR200a
+3010
5' AUGGAGUUCAGAUUACAGUGUUU UBASH3B-MRE3
3' UGUAGCAAUGGUCUGUCACAAU miR200a
+3529
5' GGCACUCUGCAAGUCCAGUGUUU UBASH3B-MRE4
P1
P2
MRE1
MRE2-4
TAA
NC
miR200a
miR200c
Relative reporter activity
P1
P1 mut
P2
P2 mut
d
UBASH3B
MB231
BT549
Relative mRNA expression
NC
miR200a
miR200c
UBASH3B
ZEB1
ZEB2
ACTIN
e
UBASH3B
MCF7
T47D
Relative mRNA expression
NC
as-200a
UBASH3B
ACTIN

Figure 3 - cont'd




Figure 4



a
MB231
BT549
% Invaded cells
100
80
60
40
20
0
NC
KD1
KD2
EGF: - + - + - +
EGFR
UBASH3B
ACTIN
b
UBASH3B >Median (159.24)
1.00
0.75
0.50
0.25
0.00
EGFR High
EGFR Low
EGFR by ROC (>33.4298)
UBASH3B Low
UBASH3B High
P = 0.0342
c
MB231-LN
MB231
NC
KD2
UBASH3B
ACTIN
MB231-LN
NC
KD2

Figure 4 - cont'd




Figure 4 - cont'd





Figure 4 - cont'd

n



o




Figure 5



a
MB231-LM2
NC
KD1
KD2
UBASH3B
ACTIN
b
Lung metastasis burden (normalized BLI signal)
NC
KD1
KD2
*
**
Days post-injection
c
NC
KD1
KD2
d
NC
KD1
KD2
e
% Survival
NC
KD1
KD2
*
**
Days post-injection
f
4T1
NC
mKD1
mKD2
UBASH3B
ACTIN

Figure 5 - cont'd




Figure 5 - cont'd




Figure 6



a
BT549
MB231
% Invaded cells
- EGF
+ EGF
Vector
UBASH3B WT
UBASH3B H391A
b
BT549
MB231
Vector
UBASH3B WT
UBASH3B H391A
EGF(h)
0 8 24 48 0 8 24 48 0 8 24 48 0 8 24 48 0 8 24 48 0 8 24 48
EGFR
UBASH3B
ACTIN
c
MB231-LN
Lung metastasis burden (normalized BLI signal)
Vector
UBASH3B WT
UBASH3B H391A
MB231-LN
MB231-LN
Vector
UBASH3B WT
UBASH3B H391A
% Survival
Days post-injection

Figure 6 – cont'd

